Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
University Health Network, Toronto
Children's Oncology Group
National Cancer Institute (NCI)
Stanford University
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
GlaxoSmithKline
St. Jude Children's Research Hospital
University of Wisconsin, Madison
Centre Leon Berard
Hospices Civils de Lyon
Essen Biotech
Children's Oncology Group
University Medical Center Groningen
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hutchmed
Cellestia Biotech AG
Bayer
Karolinska University Hospital
National Cancer Institute (NCI)
BTG International Inc.
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Children's Oncology Group
Celgene
Assistance Publique - Hôpitaux de Paris
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Wake Forest University Health Sciences
Novartis
SillaJen, Inc.
Valerio Therapeutics
University of South Florida
INSYS Therapeutics Inc
BTG International Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)